ADC Therapeutics SA
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | $81.4M | $70.8M | $69.6M | $209.9M |
| Cost of Revenue | — | $5.8M | $5.9M | $2.5M | $3.3M |
| Gross Profit | — | $75.6M | $64.9M | $67.0M | $206.6M |
| Gross Margin | — | 92.9% | 91.6% | 96.4% | 98.4% |
| Operating Expenses | |||||
| Research & Development | — | $104.0M | $109.6M | $127.1M | $186.5M |
| SG&A Expense | — | $36.6M | $41.9M | $48.4M | $74.4M |
| Operating Income | — | $-121.5M | $-130.7M | $-166.0M | $-123.3M |
| Operating Margin | — | -149.3% | -184.4% | -238.6% | -58.8% |
| Interest Expense | — | $16.3M | $50.2M | $46.3M | $36.7M |
| Pretax Income | — | $-141.6M | $-156.1M | $-195.4M | $-146.8M |
| Income Tax Expense | — | $1.0M | $166.0K | $39.1M | $227.0K |
| Net Income | — | $-142.6M | $-157.8M | $-240.1M | $-157.1M |
| Net Margin | — | -175.3% | -222.8% | -345.1% | -74.9% |
| EPS (Basic) | — | $-1.12 | $-1.62 | $-2.94 | $-2.01 |
| EPS (Diluted) | — | $-1.12 | $-1.62 | $-2.94 | $-2.01 |
| Shares Outstanding (Basic) | 127.0M | 127.1M | 97.2M | 81.7M | 78.2M |
| Shares Outstanding (Diluted) | 127.0M | 127.1M | 97.2M | 81.7M | 78.2M |
| Dividends Per Share | — | — | — | — | — |